Significance of 2',5'-oligoadenylate synthetase activity and HCV genotype in IFN therapy for type C chronic hepatitis
Related Experiment Videos
Y Karino1, S Hige, T Matsushima
1Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Abstract:
Although the mechanisms of elimination of HCV by IFN have not been fully elucidated, the 2-5A system was reported to be one of the mechanisms of the anti-viral effect of IFN. Therefore, the relationship between HCV genotype, induction of 2-5AS and clinical effect was investigated. As for the anti-viral effect during IFN therapy, in type III or IV, most patients lost HCV-RNA regardless of serum 2-5AS induction even in high HCV-RNA concentration cases. In contrast, in type II, the negativity rate of HCV-RNA became high along with an increase of serum 2-5AS activity, but in patients with high HCV-RNA concentration, HCV-RNA was persistently positive. As for the long term clinical effect of IFN therapy judged 6 months after completion of IFN therapy, HCV genotypes were closely related to the effect; that is, the patients with type III or type IV HCV genotype showed a higher complete response rate compared with the patients with type II HCV genotype. However, the relationship between the long term clinical effects and induction of serum 2-5AS during IFN therapy was obscure. These results suggest that induction of 2-5AS is closely related to the anti-viral effect during IFN administration, but the viral factors appeared to be related to long term clinical effects after cessation of IFN therapy.
Insights
Hepatitis C virus (HCV) genotypes influence treatment outcomes. While 2-5A system activity correlates with antiviral response during interferon therapy, HCV genotype appears more critical for long-term clinical effects.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Interferon (IFN) therapy is a primary treatment for Hepatitis C Virus (HCV).
- The 2-5A system is implicated in the antiviral mechanisms of IFN.
- Understanding factors influencing IFN efficacy is crucial for optimizing HCV treatment.
Purpose of the Study:
- To investigate the relationship between HCV genotype, 2-5A synthetase (2-5AS) induction, and clinical outcomes of IFN therapy.
- To differentiate the roles of viral factors and 2-5AS activity in short-term antiviral response versus long-term clinical effects.
Main Methods:
- Patients with different HCV genotypes (II, III, IV) were monitored during IFN therapy.
- Serum HCV RNA levels and 2-5AS activity were measured.
- Clinical response was assessed during therapy and 6 months post-therapy.
Main Results:
- HCV genotypes III and IV showed high HCV RNA clearance rates during IFN therapy, irrespective of 2-5AS induction.
- HCV genotype II exhibited increased HCV RNA negativity with higher 2-5AS activity, but persistent viremia in high viral load cases.
- HCV genotypes III and IV were associated with higher complete response rates post-therapy compared to genotype II.
- The correlation between long-term clinical effects and 2-5AS induction during therapy was unclear.
Conclusions:
- 2-5AS induction is linked to the immediate antiviral effect of IFN.
- HCV genotype appears to be a more significant determinant of long-term clinical outcomes after IFN therapy cessation.
- Viral factors play a key role in sustained virologic response following treatment.